- Investing.com
Future Trajectories | Analyst targets range from $8 to $15 per share, reflecting mixed views on Cryoport's ability to overcome challenges and capitalize on emerging opportunities |
Market Dynamics | Delve into Cryoport's position in the cell and gene therapy sector, balancing robust growth potential against current market softness and competitive pressures |
Financial Realities | Explore Cryoport's cost-cutting measures aimed at saving $22 million annually, and their potential impact on profitability and investor confidence |
Cold Chain Challenges | Cryoport faces headwinds in revenue growth and market positioning, with recent guidance reductions raising concerns about management's forecasting accuracy |

Metrics to compare | CYRX | Sector Sector - Average of metrics from a broad group of related Industrials sector companies | Relationship RelationshipCYRXPeersSector | |
|---|---|---|---|---|
P/E Ratio | −21.6x | −15.1x | −0.3x | |
PEG Ratio | 0.13 | 0.03 | 0.00 | |
Price / Book | 2.0x | 6.9x | 2.6x | |
Price / LTM Sales | 4.7x | 2.8x | 3.0x | |
Upside (Analyst Target) | 12.8% | −3.8% | 58.6% | |
Fair Value Upside | Unlock | 3.9% | 8.4% | Unlock |
Cryoport, Inc. provides temperature-controlled supply chain solutions in biopharma/pharma, animal health, and reproductive medicine markets worldwide. The company’s Life Sciences Services segment provides temperature-controlled logistics and biostorage, bioservices and cryopreservation services within the life science industry. Its Life Sciences Products segment manufactures, and sells cryogenic freezers, cryogenic dewars, and related ancillary accessories within the life science industry through direct sales or a distribution network. The company’s products include Cryoport Express Shippers; Cryoport Elite; Cryoport Express Cryogenic HV3 Shipping System; Smartpak Condition Monitoring System and Tec4Med, an IoT-based monitoring solutions; and Cryoport accessories. It also provides Cryoport BioStorage/Bioservices, such as Cryoport Systems Bioservices, including controlled temperature storage, kitting, labelling, fulfillment, sample management, drug return, and Qualified Person drug product release. In addition, the company offers IntegriCell services that comprise apheresis/leukapheresis collection, cryoshuttle transportation, cryo-process optimization, and cryopreservation services; Cryoport consulting services; MVE Fusion cryogenic system, a self-sustaining cryogenic freezer; and MVE Vario cryogenic system, a cryogenic freezer system. Further, it provides biological specimen cryopreservation storage and maintenance; archiving, monitoring, tracking, receipt, and delivery of samples; frozen biological specimens transportation; incoming and outgoing biological specimens management; and short-term logistics and engineering consulting services. The company was founded in 1999 and is based in Brentwood, Tennessee.